text_1: Cancers that initially benefit from epidermal growth factor receptor targeted therapies later become refractory through several mechanisms.
text_2: Our growing knowledge of resistance pathways provides an opportunity to develop new mechanism-based inhibitors and combination therapies to prevent or overcome therapeutic resistance in tumors.